Can Fite Biopharma Ltd (NASDAQ:CANF) has been given a $7.00 price target by Maxim Group in a note issued to investors on Tuesday. The firm currently has a “buy” rating on the stock. Maxim Group’s target price points to a potential upside of 318.16% from the stock’s previous close.

Separately, HC Wainwright set a $6.00 target price on Can Fite Biopharma and gave the company a “buy” rating in a research report on Thursday, August 10th.

Shares of Can Fite Biopharma (NASDAQ CANF) traded up 0.9498% on Tuesday, reaching $1.6899. The company’s stock had a trading volume of 1,374 shares. The firm’s market capitalization is $29.34 million. The firm has a 50-day moving average price of $1.70 and a 200 day moving average price of $1.77. Can Fite Biopharma has a one year low of $1.50 and a one year high of $2.67.

COPYRIGHT VIOLATION WARNING: “Maxim Group Analysts Give Can Fite Biopharma Ltd (CANF) a $7.00 Price Target” was published by American Banking News and is owned by of American Banking News. If you are reading this story on another site, it was illegally copied and republished in violation of U.S. & international trademark and copyright legislation. The correct version of this story can be viewed at https://www.americanbankingnews.com/2017/10/17/maxim-group-analysts-give-can-fite-biopharma-ltd-canf-a-7-00-price-target-2.html.

Can Fite Biopharma Company Profile

Can Fite Biofarma Ltd is an Israel-based biopharmaceutical company. The Company develops new treatments for autoimmune diseases and cancer. The Company’s drugs are CF101 for Psoriasis treatment, RA treatment, for the treatment of Keratoconjunctictivitis Sicca, for the treatment of Glaucoma, among others; and CF102 for the treatment of liver diseases.

Receive News & Ratings for Can Fite Biopharma Ltd Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Can Fite Biopharma Ltd and related companies with MarketBeat.com's FREE daily email newsletter.